A growing number of protein therapies are becoming more and more available for patient use, resulting in the need for controlled and consistent manufacturing. Because of the strict product quality and safety requirements, downstream purification of biologics is costly, often creating a major bioprocessing bottleneck (Lightfoot et al. 2004). As a result, it is critical to choose a host cell protein detection (HCP) kit that can detect an extensive range of host cell protein (high coverage) to prevent an adverse immune response. It is also important that the CHO HCP ELISA kits exhibit negligible lot-to lot variability to reduce cost due to conflicting results in the bioprocess. Canopy’s CHO HCP ELISA Kit was engineered by a bioprocessing scientist to specifically address problems with inconsistencies of current CHO HCP ELISA kits and to ultimately reduce cost in biomanufacturing.
Lightfoot EN, Moscariello JS. Bioseparations. Biotechnol Bioeng.
Canopy HCP CHO Datasheet
Please click on the link below to open a PDF discussing the competitive advantage of our CHO HCP ELISA Kit.
Canopy’s CHO HCP ELISA Kit vs Leading Competitor